Vera Therapeutics Inc (VERA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vera Therapeutics Inc (VERA) has a cash flow conversion efficiency ratio of -0.155x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-61.91 Million) by net assets ($398.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Vera Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Vera Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read VERA liabilities breakdown for a breakdown of total debt and financial obligations.
Vera Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vera Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lechwerke AG
F:LEC
|
0.109x |
|
Kinik Co
TW:1560
|
0.048x |
|
Fuchs Petrolub SE
XETRA:FPE
|
0.088x |
|
ArcSoft Corp Ltd
SHG:688088
|
0.041x |
|
Hufvudstaden AB (publ)
ST:HUFV-A
|
0.013x |
|
Shenzhen Aisidi Co Ltd
SHE:002416
|
0.147x |
|
Liechtensteinische Landesbank Aktiengesellschaft
F:LLS1
|
-0.063x |
|
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
|
0.063x |
Annual Cash Flow Conversion Efficiency for Vera Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Vera Therapeutics Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Vera Therapeutics Inc (VERA) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $577.15 Million | $-134.68 Million | -0.233x | +74.26% |
| 2023-12-31 | $101.69 Million | $-92.18 Million | -0.907x | -3.14% |
| 2022-12-31 | $76.91 Million | $-67.60 Million | -0.879x | -158.00% |
| 2021-12-31 | $69.59 Million | $-23.71 Million | -0.341x | -187.44% |
| 2020-12-31 | $-89.35 Million | $-34.81 Million | 0.390x | +38.39% |
| 2019-12-31 | $-36.55 Million | $-10.29 Million | 0.282x | -- |
About Vera Therapeutics Inc
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company's lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-adm… Read more